OTHER (INCOME)/EXPENSE, NET - Narrative (Details) shares in Millions, $ in Millions	3 Months Ended		9 Months Ended	36 Months Ended	38 Months Ended
	Sep. 30, 2023 USD ($)	Mar. 31, 2022 USD ($)	Sep. 30, 2023 USD ($)	Sep. 30, 2026 USD ($)	Sep. 30, 2026 USD ($) payment	Aug. 31, 2023 shares	Jul. 31, 2023 lawsuit
Nimbus Therapuetics TYK2 Inhibitor
Licensing Arrangements [Line Items]
Proceeds from legal settlements		$ 40	$ 400
AZ AB
Licensing Arrangements [Line Items]
Number of litigations | lawsuit							2
Settlement amount	$ 384
AZ AB | Forecast
Licensing Arrangements [Line Items]
Settlement amount				$ 560
Number of payments | payment					4
Proceeds from legal settlements					$ 418
BeiGene
Licensing Arrangements [Line Items]
Litigation settlement, number of shares transferred (in shares) | shares						23.3
Litigation settlement expense	$ 322